232 related articles for article (PubMed ID: 22579366)
1. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
Kagoya Y; Nannya Y; Kurokawa M
Leuk Res; 2012 Aug; 36(8):1016-21. PubMed ID: 22579366
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide in the treatment of multiple myeloma.
Kastritis E; Dimopoulos MA
Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
[TBL] [Abstract][Full Text] [Related]
5. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang L; Ran X; Wang B; Sheng Z; Liu L
Hematol Oncol; 2012 Jun; 30(2):57-61. PubMed ID: 21809367
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
8. [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma].
Ikebe T; Ogata M; Miyazaki M; Miyazaki Y; Ohtsuka E; Saburi Y; Goto K; Ikewaki J; Kohno K; Uno N; Imamura T; Akagi T; Kadota J
Rinsho Ketsueki; 2010 Feb; 51(2):114-21. PubMed ID: 20379102
[TBL] [Abstract][Full Text] [Related]
9. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
10. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV
Mayo Clin Proc; 2003 Jan; 78(1):34-9. PubMed ID: 12528875
[TBL] [Abstract][Full Text] [Related]
11. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
12. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
13. Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis.
Wang L; Cui J; Liu L; Sheng Z
Hematol Oncol; 2012 Dec; 30(4):163-9. PubMed ID: 22189704
[TBL] [Abstract][Full Text] [Related]
14. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
16. The role of thalidomide in multiple myeloma.
Schwab C; Jagannath S
Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
19. Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.
Yakoub-Agha I; Mary JY; Hulin C; Doyen C; Marit G; Benboubker L; Voillat L; Moreau P; Berthou C; Stoppa AM; Maloisel F; Rodon P; Dib M; Pegourie B; Casassus P; Slama B; Damaj G; Zerbib R; Harousseau JL; Mohty M; Facon T;
Eur J Haematol; 2012 Mar; 88(3):249-59. PubMed ID: 22023551
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy for multiple myeloma with particular emphasis on thalidomide.
Dürk HA
Onkologie; 2006 Dec; 29(12):582-90. PubMed ID: 17202830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]